RAS inhibitors – Talk Bio

Actionable Insights Powered by AI

Revolution Medicines Rejects Merck’s Acquisition Bid, Stands Firm on Valuation Amid Ongoing Interest

Revolution Medicines; Merck; acquisition talks; RAS inhibitors; daraxonrasib; biotech M&A